NEWTON, Mass./EWORLDWIRE/July 22, 2008 --- Life Science Angels (LSA), a Bay Area healthcare angel investment group focused on biotechnology and medical device companies, has made a further investment in NeuroHealing Pharmaceuticals. With this third round since March, 2006, LSA has invested over $650,000 in NeuroHealing.NeuroHealing Pharmaceuticals is a specialty clinical stage neuroscience company focusing on restoring cognitive and physical function in brain injury patients, and developing supportive care products for neurodegenerative diseases. NeuroHealing is developing reprofiled drug candidates, each with early evidence of clinical efficacy and extensive human safety data, and market-driven innovative formulations and/or delivery systems.
"We are pleased to have the continued financial backing and support of LSA," said Neal M. Farber, Ph.D., CEO of NeuroHealing. "LSA represents an extremely knowledgeable and successful group of life science entrepreneurs who share our excitement and commitment to NeuroHealing's novel therapeutic programs for debilitating CNS conditions and supportive care."
LSA Board member and biotechnology screening committee co-chair Karen Talmadge, Ph.D. will continue to advise the company, and be an observer at NeuroHealing Board meetings. Dr. Talmadge, formerly co-founder and chief science officer at Kyphon Inc., recently acquired by Medtronic for $4.2 B, is now Chief Science Officer, Kyphon Products, for the Medtronic Spinal and Biologics' business.
About Life Science Angels (LSA)
Life Science Angels Inc. is the premier angel investment group focused solely on biotechnology and medical device companies. LSA was established by senior life science executives and experienced angel investors to meet the need for seed and early-stage funding for life science companies. By identifying promising investment opportunities and bringing together members who add sector-specific experience, broad networks, and financial backing, LSA is able to assist emerging companies to position themselves for later-round venture-backed funding. Since 2005, LSA has invested $17 million in 23 companies that have received an additional $350+ million on follow-on funding from VCs.
About NeuroHealing Pharmaceuticals
NeuroHealing Pharmaceuticals Inc. ('http://www.NeuroHealing.com') is a clinical stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system. Programs include:
. NH001, a dopaminergic agent in Phase II testing to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state
. NH004, an anticholinergic agent in a convenient intra-orally dissolving film in Phase II testing to help treat Parkinsons and motor neuron patients who suffer from sialorrhea (drooling)
. NH02D, a novel mechanism compound to accelerate the rehabilitation outcomes of stroke patients who remain with chronic motor and cognitive disabilities.
For further information contact:
Daniel Katzman, President
NeuroHealing Pharmaceuticals Inc.
617.331.4111
info@NeuroHealing.com
(Top)